In relapsing-remitting multiple sclerosis, activation of the peripheral immune system can lead to focal inflammation within the CNS. Over the past three decades, therapeutic development has been ...

Autoimmune diseases, such as multiple sclerosis (MS), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA), affect ...

The rates of people MS advancing from RRMS to SPMS have decreased significantly in the past decades, according to a 30-year ...

The University of Cincinnati joins a Phase 1 clinical trial testing CAR-T cell therapy for MS, exploring this cancer ...

Nearly two-thirds of MS patients showed no signs of disability progression five years after having a stem cell transplant, a ...

Panelists discuss how chronic neuroinflammation involves distinct mechanisms from acute relapses—including microglial ...

Although there is no cure for multiple sclerosis, so-called disease-modifying drugs can reduce the frequency of relapses and slow or delay the progression of disability. Fewer treatments are available ...

Briumvi and Ocrevus are both used to treat relapsing forms of multiple sclerosis (MS). Studies of Briumvi and studies of Ocrevus have shown that both drugs are effective for this use.

It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis.

New research led by a St. Michael’s Hospital clinician-scientist and published in the prestigious New England Journal of Medicine suggests that a therapy called Tolebrutinib could reduce disability ...